November 20, 2007 - ...This new clinical study follows the recent announcement of promising top-line results from a phase 2a study in asthmatic smokers, where TPI 1020 showed a good safety and tolerability profile, in addition to certain anti-inflammatory effects which could be potentially beneficial in
COPD (
see press release of September 11, 2007). COPD is a respiratory disease caused by chronic inflammation of the lungs and bronchi and represents the third-leading cause of death in the United States...
[PDF] NicOx' Press Release -
PDF en Français -
[PDF] Topigen's Press Release -
